Drug Profile
PRO 156
Alternative Names: PRO-156Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Laboratorios Sophia
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Eye-disorders in Mexico (Ophthalmic, Drops)
- 01 Dec 2013 Laboratorios Sophia completes a phase I trial in Eye disorders in Mexico (NCT01871077)
- 01 Sep 2013 Phase-I clinical trials in Eye disorders in Mexico (Ophthalmic)